Gemcitabine plus taxane combinations in non-small cell lung cancer.
Among the relatively new cytotoxic agents that are active in non-small cell lung cancer, gemcitabine and the taxanes (paclitaxel and docetaxel) are certainly of particular interest due to their essentially nonoverlapping toxicities and single-agent activities, which compare favorably with single-agent cisplatin. For these reasons, new combinations including these agents are being tested in dose-finding studies in phase II and III trials. Combinations of gemcitabine with a taxane, with or without a platinum compound, represent new and promising regimens for the treatment of non-small cell lung cancer and other tumor types.
Giaccone
G
G
Department of Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D017671:Platinum Compounds / Q000008:administration & dosage; D000093542:Gemcitabine
D017671:Platinum Compounds; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine